Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i.v. respectively every 28 days. Out of 25 patients evaluable for response 9 patients achieved a partial remission (36%) for a median duration of 20.5 weeks. The main side effects were leukopenia (grade 3-4 in 70%) and nausea-vomiting (grade 3-4 in 27%). Alopecia was present only in 5 patients (17%). Three patients demonstrated instrumental signs of cardiotoxicity without clinical symptoms.
Martoni
A
A
Oncology Division, S. Orsola Malpighi Hospital, Bologna, Italy.
Rani
P
P
Ercolino
L
L
Canova
N
N
Pannuti
F
F
D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009325:Nausea / Q000139:chemically induced; D014839:Vomiting / Q000139:chemically induced
D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil